|Bid||0.590 x 1000|
|Ask||0.679 x 1000|
|Day's Range||0.620 - 0.652|
|52 Week Range||0.450 - 2.000|
|Beta (3Y Monthly)||3.80|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 7, 2018 - Nov 12, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||1.10|
ARCA Biopharma, a Westminster biotech company, has been given an additional 180 days to regain compliance with Nasdaq’s $1 per share minimum bid price requirement, according to an SEC form filed Tuesday. “Our Nasdaq listing is obviously very important to the company and our shareholders, so we are very focused on regaining compliance with the Nasdaq minimum closing bid price continued listing requirement,” Derek Cole, the company’s investor relations leader, said in an email. “The additional 180-day compliance period affords ARCA the opportunity to potentially regain compliance.” ARCA Biopharma is the 12th largest biotechnology/biosciences company in Colorado as ranked by number of employees, according to Denver Business Journal research.
NEW YORK, NY / ACCESSWIRE / October 2, 2018 / U.S. equities were mixed on Monday after the U.S. and Canada agreed to revise the current North American Free Trade Agreement. The Dow Jones Industrial Average ...
ARCA biopharma, Inc. (ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted therapies for cardiovascular diseases, today announced that it has submitted a Special Protocol Assessment (SPA) request to the U.S. Food and Drug Administration (FDA). The request is part of the Company’s ongoing interaction with the FDA focused on the planned Phase 3 clinical development program of GencaroTM (bucindolol hydrochloride) as a genetically-targeted treatment for heart failure (HF) patients at risk for atrial fibrillation (AF). The FDA’s SPA process is designed to facilitate the FDA’s review and approval of drugs by allowing FDA to evaluate the proposed design and size of certain clinical trials that are intended to form the primary basis for determining a drug product’s efficacy and safety.
WESTMINSTER, Colo., Aug. 09, 2018-- ARCA biopharma, Inc., a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted therapies for cardiovascular diseases, today ...
Last month, for instance, GT Biopharma (GTBP) announced a Material Transfer Agreement between a Major Pharmaceutical Company and Dr. Daniel Vallera, Director, Section of Molecular Cancer Therapeutics at the Masonic Cancer Center, University of Minnesota. This Major Pharmaceutical Company will be supplying a formulation of their multibillion-dollar, widely prescribed oncology drug, which has been approved for use in several hematologic malignancies to Dr. Vallera to be used in this study.
CORAL GABLES, FL / ACCESSWIRE / July 31, 2018 / The Nasdaq iShares Biotechnology Index (IBB) has taken a turn toward ''greener pastures.'' The ETF rose by more than 1.2% on Tuesday as a number of biotech stocks moved higher in early morning trading. GT Biopharma (GTBP) is an immuno-oncology biotechnology company focused on innovative treatments based on the company's proprietary platforms. Earlier this month the company announced the addition of Dr. John N. Bonfiglio to GT Biopharma's Board of Directors.
ARCA biopharma, Inc. (ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted therapies for cardiovascular diseases, today announced that it has received guidance from the U.S. Food and Drug Administration (FDA) following an End-of-Phase 2 meeting regarding the Phase 3 program for ARCA’s pharmacologically unique beta-blocker Gencaro as a potential genetically-targeted treatment for atrial fibrillation (AF) patients with heart failure (HF). Based on review of the Phase 2 GENETIC-AF trial results, as well as its alignment with previous Phase 3 pharmacogenetic substudy data, the FDA stated that data from a single pivotal Phase 3 clinical trial may be sufficient to support approval of Gencaro for the treatment of AF in patients with HF.
NEW YORK, NY / ACCESSWIRE / July 31, 2018 / Biotech stocks Progenics and ARCA biopharma were both soaring on Monday. While ARCA had no news to explain its 40% climb, shares of Progenics soared higher after ...
Research coverage has been initiated by WallStEquities.com on Aimmune Therapeutics Inc. (NASDAQ: AIMT), Alkermes PLC (NASDAQ: ALKS), Aratana Therapeutics Inc. (NASDAQ: PETX), and ARCA biopharma Inc. (NASDAQ: ABIO). The majority of Biotech companies research and develop products for the healthcare market.
NEW YORK, NY / ACCESSWIRE / May 11, 2018 / vTv Therapeutics and ARCA biopharma were both soaring in Thursday's trading session. Both had news as catalysts to drive shares higher with vTv Therapeutics announcing ...
LONDON, UK / ACCESSWIRE / May 10, 2018 / If you want a free Stock Review on AIMT sign up now at www.wallstequities.com/registration. All you have to do is sign up today for this free limited time offer by clicking the link below.
Stock Monitor: ARCA biopharma Post Earnings Reporting LONDON, UK / ACCESSWIRE / April 03, 2018 / Active-Investors.com has just released a free research report on Insmed Inc. (NASDAQ: INSM ). If you want ...
Case in point: Arca Biopharma Inc (NASDAQ:ABIO), whose shares are jumping 40% on Tuesday. Why? The drug maker announced positive results from its Phase 2B trial evaluating GencaroTM (bucindolol hydrochloride) as a genetically-targeted treatment for atrial fibrillation (AF) in patients with heart failure and reduced left ventricular ejection fraction (HFrEF). In all patients, Gencaro demonstrated a similar treatment benefit compared to the active control, metoprolol succinate (TOPROL-XL).
ARCA biopharma, Inc. (NASDAQ:ABIO) has had a rough start to the week this week. The company put out a release detailing the progress of a phase II trial that was put in place to investigate an asset called Gencaro, which ARCA is trying to demonstrate can be a safe and effective treatment for atrial fibrillation […] The post ARCA biopharma And ObsEva Just Put Out Clinical Trial Data appeared first on Market Exclusive.
If you are a shareholder in ARCA biopharma Inc’s (NASDAQ:ABIO), or are thinking about investing in the company, knowing how it contributes to the risk and reward profile of yourRead More...
In this article, I’m going to take a look at ARCA biopharma Inc’s (NASDAQ:ABIO) latest ownership structure, a non-fundamental factor which is important, but remains a less discussed subject amongRead More...
ARCA biopharma Inc (NASDAQ:ABIO), a USD$14.69M small-cap, is a healthcare company operating in an industry, which faces key trends such as rising demand fuelled by an aging population and theRead More...
Michael Bristow took the helm as ARCA biopharma Inc’s (NASDAQ:ABIO) CEO and grew market cap to USD$14.69M recently. Understanding how CEOs are incentivised to run and grow their company isRead More...